Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.51 |
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6922604 | 0.88 | FLT3 (0.43) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL14161892 | 0.85 | FLT3 (0.49) | FLT3KDRFGFR3KCNH2GRM2 | |
| SCHEMBL6921743 | 0.84 | FLT3 (0.53) | FLT3KDRFGFR3GRIN2BALDH1A1 | |
| SCHEMBL12042167 | 0.82 | GRM5 (0.41) | FLT3KDRFGFR3NPC1ALDH1A1 | |
| SCHEMBL6922815 | 0.78 | KDR (0.44) | KDRFGFR3NPC1ALDH1A1RAB9A | |
| SCHEMBL6922630 | 0.78 | KDM4E (0.39) | KDRFGFR3NPC1ALDH1A1RAB9A | |
| SCHEMBL12059189 | 0.78 | FLT3 (0.45) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6922507 | 0.76 | FLT3 (0.43) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6921936 | 0.76 | FLT3 (0.44) | FLT3KDRFGFR3GRM2GRIN2B | |
| SCHEMBL6921226 | 0.75 | GRM5 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | FLT3 2845/4885KDR 3370/4885FGFR3 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.